Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (744)	9/27/2005 8:37:44 PM
From: tuck	Read Replies (1) of 946

>>Back in July when the pooled Stellar 3 and 4 data was presented for the first time, indicating a survival advantage for women, there was no effect at all on the share price. Today, when data from a largerly irrelevant single-arm phase II study is added, the share price shoots up with 50 %. << Data in July: Message 21479638 The pooled data somehow make the p values look noticeably better. Perhaps that's what folks were reacting to today. Message 21740660 Still need good Pixantrone results to keep this puppy over $3, IMO. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next